Paola Grandi, PhD Birth Date - American Society of Gene & Cell ...
Paola Grandi, PhD Birth Date - American Society of Gene & Cell ... Paola Grandi, PhD Birth Date - American Society of Gene & Cell ...
HONORS1996 B.Sc. in Biology: degree with 110/110 cum laude from University of Ferrara;1997 M.Sc. in Genetic: degree with distinction;2001 Ph.D degree with optimum from University of Ferrara;2001 Only fellowship for US study from University of Ferrara.2005 travel award for the best oral presentation at the International Herpesvirus Workshop, Turku, Finland.2012 Scientist of the month (march) from American Society for Gene and Cell therapy.Under revision:PUBLICATIONSLucia Mazzacurati, Marco Marzulli, Bonnie Reinhard, Yoshitaka Miagawa, Nino Chiocca, Joseph Glorioso, PaolaGrandimir124-controlled HSV1 based oncolytic vecto for treatment of Glioblastoma Multiforme (Submitted cancer research)Publications in Scientific Journals:1. Uchida H, Chan J, Shrivastava I, Reinhart B, Grandi P, Glorioso JC, Cohen JB. Novel mutations in gB and gHcircumvent the requirement of known gD Receptors in herpes Simplex Virus 1 Entry and cell-to-cell spread. JVirol. 2013 Feb;87(3):1430-42. doi: 10.1128/JVI.02804-12. Epub 2012 Nov 14.2. Hiroaki Uchida, Marco Marzulli, William F. Goins, Janet Chan, Chang-Sook Hong, Lucia Mazzacurati, Ji Y.Yoo, Amy Haseley, Hiroshi Nakashima, Kenji Nakano, Hyunjung Baek, Heechung Kwon, Izumi Kumagai,Masahide Kuroki, Balveen Kaur, E. Antonio Chiocca, Paola Grandi, Justus B. Cohen, and Joseph C. Glorioso.Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-RetargetedOncolytic Herpes Simplex Virus. Mol. Therapy 2012, Oct 163. Bonnie Reinhart, Lucia Mazzacurati, Adriana Forero, Chang-Sook Hong, Junichi Eguchi, Hideho Okada, WendyFellow, Ajay Niranjan, Justus Cohen, J. C. Glorioso and Paola Grandi. Inhibition of Indoleamine-2,3-Dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Advances in Virology. 2012;2012:8154654. Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Gene Ther. 2010Sep;17(9):655-63. Epub 2010 May 28.5. Uchida H, Chan J, Goins WF, Grandi P, Kumagai I. Cohen JB, and Glorioso, JC. A double mutation inglycoprotein B compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. JVirol. Dec; 84(23): 12200-9, 2010.6. Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC, Grandi P. Ectopic matrixmetalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther.Oct; 17(10): 1200-5, 2010.7. Frampton AR Jr, Uchida H, von Einem J, Goins WF, Grandi P, Cohen JB, Osterrieder N, Glorioso JC. Equineherpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. VetMicrobiol. 2010 Feb 24;141(1-2):12-21. Epub 2009 Aug 8.8. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSVvectors for glioblastoma therapy. Expert Rev Neurother. 2009 Apr;9(4):505-179. Uchida H, Shah WA, Ozuer A, Frampton AR Jr, Goins WF, Grandi P, Cohen JB, Glorioso JC. Generation ofherpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEMexpressingcells and identification of mutations that rescue nectin-1 recognition. J Virol. 2009 Apr;83(7):2951-61.10. H. Li, D. Krisky, P. Grandi, R. Baskaran, J. C. Glorioso . HSV-1 ICP0 activates Chk2 to induce G2/M arrest andto enhance virus growth. Virology. 2008 May 25;375(1):13-232
11. Bozac, Berto E., VasquezF., Grandi P., Caputo A., Mnaservigi R., Ensoli B., Marconi P. Expression of HumanImmunodeficiency Virus Type 1 tat from a replication-deficient herpes simplex vector induces antigen-specific Tcell responses. Vaccine. 2006 Nov 30;24(49-50):7148-58. Epub 2006 Jul 12.12. Grandi P., Fernadez J., Szemntirmai O., Carter R., Breakefield X., Sena- Esteves M. Targeting HSV-1 virions forspecific binding to Epidermal Growth Factor Receptro-vIII on Tumor cells. (2006) Mol. Therapy. 13: 16813. Trevor McKee 1 , Paola Grandi 1 , Wilson Mok, George Alexandrakis, Numpon Insin, John P. Zimmer, Moungi G.Bawendi, Yves Boucher Xandra O. Breakefield and Rakesh K. Jain. Degradation of fibrillar collagen within solidtumors improves the efficacy of oncolytic viral therapy (2006). Cancer Research 66 (5): 2509-13 1 authorscontributed equally14. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1virions engineered for specific binding to cell surface receptor (2004) Mol. Therapy, 9: 419-27.15. Grandi P., Spear M., Breakefield X., Wang S. Targeting HSV-1 vectors (2004). Methods, 33:179-186.16. Spear M., Schuback D., Miyata K., Grandi P., Sun F., Yoo L., Nguyen A., Brandt C.R., Breakefield X. HSV-1amplicon peptide display vector (2003). Journal of Virological Methods; 107: 71-79.17. Garrafa E., Argnani R, Marconi P., Grandi P., Zerbinati A., Bozac A., Berto E., Gardo G., Fugagnoli S.,Catalano C., Grossi M.P., Balboni P.G., Manservigi R. Virus erpetici come vettori vaccinali. (2003). L’IgieneModerna 119: 251-266.18. Grandi P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1amplicon vector engineered for specific binding to pseudo His-tag receptor. (2002) Mol. Ther. 5: 320.19. Caselli E., Grandi P., Argnani R., Balboni P.G., Braga F. and Manservigi R. Mice genetic immunization withplasmid DNA encoding a secreted form of HSV-1 gB1 induce a protective immune response against HSV-1infection and establishment of latency (2001). Intervirology; 44: 1-7.20. Monini, P., de Lellis L, Rimesi, P., GRANDI P., Franco M, Leone L, Rosso R, Rossi T., Aiuti F, Ledi G. L.,Ensoli, B., Cassai, E (1997). Presence of HHV-8 DNA in semen of inmmunocompetent HIV-negative individualsfrom different geographical areas in Italy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESAND HUMAN RETROVIROLOGY, ISSN: 1077-9450Book Chapters:1. Grandi, P., Bein, K., Hadjipanayis, C. G., Wolfe, D., Breakefield, X. O. Glorioso, J.C. “Application of HSV-1Vectors to the Treatment of Cancer”. "Viral Therapy of Cancer"Book, edited by Kevin Harrington, HardevPandha and Richard Vile (April 2008).2. Kohn, D.B., Carter, B., Glorioso, J.C. , Grandi P. “Gene Therapy and Viruses”. Clinical Virology. Chapter 20.2008PROFESSIONAL ACTIVITIES2005-2010 Assistant Editor for the Nature Group Journal, Gene Therapy2010-present ASGCT webtaskforce2011 ASGCT Cancer Gene & Cell Therapy Commette2012 Founder of ACAREF: Allied Community Ataxia Research FoundationTEACHING EXPERIENCE2008-present Integrated Cases Studies (ICS) course – Medical Students2010– present Experimental Virology - MVM PhD program2010 Medical Microbiology (MS1)ACTIVERESEARCH3
- Page 1: CURRICULUM VITAEName: Paola Grandi,
- Page 5 and 6: In this proposal, experiments are o
- Page 7 and 8: GRANDI P. (2005). In vivo imaging o
- Page 9: Miyagawa Y, Cohen J, Simonato M, GR
11. Bozac, Berto E., VasquezF., <strong>Grandi</strong> P., Caputo A., Mnaservigi R., Ensoli B., Marconi P. Expression <strong>of</strong> HumanImmunodeficiency Virus Type 1 tat from a replication-deficient herpes simplex vector induces antigen-specific Tcell responses. Vaccine. 2006 Nov 30;24(49-50):7148-58. Epub 2006 Jul 12.12. <strong>Grandi</strong> P., Fernadez J., Szemntirmai O., Carter R., Breakefield X., Sena- Esteves M. Targeting HSV-1 virions forspecific binding to Epidermal Growth Factor Receptro-vIII on Tumor cells. (2006) Mol. Therapy. 13: 16813. Trevor McKee 1 , <strong>Paola</strong> <strong>Grandi</strong> 1 , Wilson Mok, George Alexandrakis, Numpon Insin, John P. Zimmer, Moungi G.Bawendi, Yves Boucher Xandra O. Breakefield and Rakesh K. Jain. Degradation <strong>of</strong> fibrillar collagen within solidtumors improves the efficacy <strong>of</strong> oncolytic viral therapy (2006). Cancer Research 66 (5): 2509-13 1 authorscontributed equally14. <strong>Grandi</strong> P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1virions engineered for specific binding to cell surface receptor (2004) Mol. Therapy, 9: 419-27.15. <strong>Grandi</strong> P., Spear M., Breakefield X., Wang S. Targeting HSV-1 vectors (2004). Methods, 33:179-186.16. Spear M., Schuback D., Miyata K., <strong>Grandi</strong> P., Sun F., Yoo L., Nguyen A., Brandt C.R., Breakefield X. HSV-1amplicon peptide display vector (2003). Journal <strong>of</strong> Virological Methods; 107: 71-79.17. Garrafa E., Argnani R, Marconi P., <strong>Grandi</strong> P., Zerbinati A., Bozac A., Berto E., Gardo G., Fugagnoli S.,Catalano C., Grossi M.P., Balboni P.G., Manservigi R. Virus erpetici come vettori vaccinali. (2003). L’IgieneModerna 119: 251-266.18. <strong>Grandi</strong> P., Wang S., Schuback D., Krasnykh V., Spear M., Curiel D., Manservigi R., Breakefield X. HSV-1amplicon vector engineered for specific binding to pseudo His-tag receptor. (2002) Mol. Ther. 5: 320.19. Caselli E., <strong>Grandi</strong> P., Argnani R., Balboni P.G., Braga F. and Manservigi R. Mice genetic immunization withplasmid DNA encoding a secreted form <strong>of</strong> HSV-1 gB1 induce a protective immune response against HSV-1infection and establishment <strong>of</strong> latency (2001). Intervirology; 44: 1-7.20. Monini, P., de Lellis L, Rimesi, P., GRANDI P., Franco M, Leone L, Rosso R, Rossi T., Aiuti F, Ledi G. L.,Ensoli, B., Cassai, E (1997). Presence <strong>of</strong> HHV-8 DNA in semen <strong>of</strong> inmmunocompetent HIV-negative individualsfrom different geographical areas in Italy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESAND HUMAN RETROVIROLOGY, ISSN: 1077-9450Book Chapters:1. <strong>Grandi</strong>, P., Bein, K., Hadjipanayis, C. G., Wolfe, D., Breakefield, X. O. Glorioso, J.C. “Application <strong>of</strong> HSV-1Vectors to the Treatment <strong>of</strong> Cancer”. "Viral Therapy <strong>of</strong> Cancer"Book, edited by Kevin Harrington, HardevPandha and Richard Vile (April 2008).2. Kohn, D.B., Carter, B., Glorioso, J.C. , <strong>Grandi</strong> P. “<strong>Gene</strong> Therapy and Viruses”. Clinical Virology. Chapter 20.2008PROFESSIONAL ACTIVITIES2005-2010 Assistant Editor for the Nature Group Journal, <strong>Gene</strong> Therapy2010-present ASGCT webtaskforce2011 ASGCT Cancer <strong>Gene</strong> & <strong>Cell</strong> Therapy Commette2012 Founder <strong>of</strong> ACAREF: Allied Community Ataxia Research FoundationTEACHING EXPERIENCE2008-present Integrated Cases Studies (ICS) course – Medical Students2010– present Experimental Virology - MVM <strong>PhD</strong> program2010 Medical Microbiology (MS1)ACTIVERESEARCH3
Change language